Trial reportDiabetes2019
Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program.
Trial report in Diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies.Diabetes care · 2022Pooled it
- Circulating Metabolite Biomarkers of Glycemic Control in Youth-Onset Type 2 Diabetes.Diabetes care · 2024Trial
- Shared and distinct metabolomics profiles associated with microvascular complications in the Diabetes Prevention Program Outcomes Study.Diabetologia · 2026Article
- Longitudinal analysis of genetic and environmental interplay in human metabolic profiles and the implication for metabolic health.Genome medicine · 2025Article
- The gut microbiota intervenes in glucose tolerance and inflammation by regulating the biosynthesis of taurodeoxycholic acid and carnosine.Frontiers in cellular and infection microbiology · 2024Article
- The role of exercise and hypoxia on glucose transport and regulation.European journal of applied physiology · 2023Review
- Untargeted metabolomic profiling identifies serum metabolites associated with type 2 diabetes in a cross-sectional study of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study.American journal of physiology. Endocrinology and metabolism · 2023Article
- A roadmap to achieve pharmacological precision medicine in diabetes.Diabetologia · 2022Review
- Cardio-Onco-Metabolism - Metabolic vulnerabilities in cancer and the heart.Journal of molecular and cellular cardiology · 2022Review
- Metabolomics of Type 1 and Type 2 Diabetes: Insights into Risk Prediction and Mechanisms.Current diabetes reports · 2022Review
- A metabolome-wide association study of in utero metal and trace element exposures with cord blood metabolome profile: Findings from the Boston Birth Cohort.Environment international · 2022Article
- Diagnostic Performance of Sex-Specific Modified Metabolite Patterns in Urine for Screening of Prediabetes.Frontiers in endocrinology · 2022Article
- New mediators in diabetes pathogenesis: Exosomes and metabolites.Journal of diabetes investigation · 2021Article
- Antidiabetic Effect of Noodles Containing Fermented Lettuce Extracts.Metabolites · 2021Article
- Chronic Kidney Disease Cohort Studies: A Guide to Metabolome Analyses.Metabolites · 2021Review
- Per- and polyfluoroalkyl substance plasma concentrations and metabolomic markers of type 2 diabetes in the Diabetes Prevention Program trial.International journal of hygiene and environmental health · 2021Article
- Metabolic Architecture of Acute Exercise Response in Middle-Aged Adults in the Community.Circulation · 2020Article
- Metabolomics and Proteomics in Type 2 Diabetes.Circulation research · 2020Review
- Toward a Standardized Strategy of Clinical Metabolomics for the Advancement of Precision Medicine.Metabolites · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Novel biomarkers of type 2 diabetes (T2D) and response to preventative treatment in individuals with similar clinical risk may highlight metabolic pathways that are important in disease development. We profiled 331 metabolites in 2,015 baseline plasma samples from the Diabetes Prevention Program (DPP). Cox models were used to determine associations between metabolites and incident T2D, as well as whether associations differed by treatment group (i.e., lifestyle [ILS], metformin [MET], or placebo [PLA]), over an average of 3.2 years of follow-up. We found 69 metabolites associated with incident T2D regardless of treatment randomization. In particular, cytosine was novel and associated with the lowest risk. In an exploratory analysis, 35 baseline metabolite associations with incident T2D differed across the treatment groups. Stratification by baseline levels of several of these metabolites, including specific phospholipids and AMP, modified the effect that ILS or MET had on diabetes development. Our findings highlight novel markers of diabetes risk and preventative treatment effect in individuals who are clinically at high risk and motivate further studies to validate these interactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.